Instruction for use: Brinsulrapi MC 40 IU/ml

ATX Code A10AB Short-acting insulins and their analogs for injection

Active substance Insulin soluble [human biosynthetic]

Pharmacological group

insulins

Nosological classification (ICD-10)Z31.1 Artificial insemination

E14 Unspecified diabetes mellitus

Severe vascular complication of diabetes, Diabetes, Diabetic asthenia, Thyroid dysfunction, Diabetes,Obesity in the background of diabetes

Composition and form of release

1 ml of solution for injection contains porcine highly purified monocomponent insulin 40 ED, as well as 3 mg of metacresol as a preservative; In glass bottles of 10 ml, in a cardboard bundle 1 bottle.

Characteristic

Pork monocomponent insulin in the form of a neutral solution. Colorless or almost colorless, transparent or almost transparent liquid.

pharmachologic effect

Pharmacological action - hypoglycemic.

It lowers the level of glucose in the blood, increases its absorption by tissues, activates glycogenogenesis, synthesis of protein and lipids, inhibits lipolysis, glycogenolysis and conversion of amino acids into glucose.

Clinical Pharmacology

The preparation of insulin is fast and short-acting. The effect develops 30 minutes after the SC administration, reaches a maximum in the interval 1-3 hours and lasts 8 hours.

Indications

Diabetes mellitus (type 1) in children and adults, diabetes mellitus (type 2) (in the case of resistance to oral hypoglycemic drugs, including partial for combination therapy, against intercurrent diseases, during pregnancy).

Contraindications

Hypersensitivity, hypoglycemia.

Side effects

Hypoglycemia (pallor of the skin, increased sweating, palpitation, tremor); Allergic reactions (skin rash, rarely - angioedema, extremely rare - anaphylactic shock); Hyperemia, itching, lipodystrophy (with prolonged use) at the injection site; Transient refractive disorders (usually at the beginning of therapy).

Interaction

MAO inhibitors, nonselective beta-blockers, sulfonamides, anabolic steroids, tetracyclines, clofibrate, cyclophosphamide, fenfluramine, preparations containing ethanol increase hypoglycemic effect; Oral contraceptives, glucocorticoids, thyroid hormones, thiazide diuretics, heparin, lithium preparations, tricyclic antidepressants - weaken. Reserpine and salicylates can both weaken and enhance hypoglycemic action.

Dosing and Administration

P / to, the dose is determined individually. The solution must be entered immediately after typing in the syringe. A daily dose exceeding 0.6 U / kg should be administered as two or more injections in different areas of the body.

Overdose

Symptoms: a sharp increase in sweating, palpitation, tremor, hunger, excitement, paresthesia in the mouth, pallor, headache; In severe cases - hypoglycemic coma.

Treatment: ingestion of sugar or foods rich in carbohydrates; In severe cases - the introduction of glucose (20-40 ml 40% solution iv) and glucagon (1 mg IM).

special instructions

Patients receiving more than 100 units / day of Brinsulapi MK, when changing the drug, it is advisable to hospitalize.

The transition from one type of insulin to another should be carried out under the control of blood glucose.

At primary appointment, change of a kind of insulin or occurrence during treatment of stressful situations the ability to control vehicles and mechanisms, to other potentially dangerous kinds of activity requiring attention and speed of reaction is possible.

When changing the nature and diet, significant physical exertion, infectious diseases, surgical interventions, pregnancy, thyroid dysfunction, Addison's disease, hypopituitarism, renal insufficiency, and in patients older than 65 years, the dosage should be adjusted.

Insulin lowers tolerance to alcohol.

storage Conditions

In the dark place at a temperature of 2-8 ° C. Do not freeze.

Keep out of the reach of children.

Shelf life

2.5 years.

Do not use after the expiry date printed on the package.